Who is sponsoring NCT04609930?

NCT04609930 is sponsored by University Hospital, Montpellier.

What drugs are being tested in NCT04609930?

Interventions in NCT04609930: Anti-PD-1 or anti-PD-L1.

What condition does NCT04609930 study?

NCT04609930 studies Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies.

Is NCT04609930 still recruiting?

NCT04609930 is currently completed. Last updated 23 December 2021.

Last reviewed 2021-12-23 · How we verify

NCT04609930: ImmunEO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

Completed Last updated 23 December 2021

What this trial tests

trial testing Anti-PD-1 or anti-PD-L1 in Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies in 143 participants. Completed in 31 August 2021.

Timeline

30 October 2020

Primary endpoint
31 August 2021

31 August 2021

Quick facts

Lead sponsor	University Hospital, Montpellier
Status	Completed
Study type	OBSERVATIONAL
Enrollment	143
Start date	30 October 2020
Primary completion	31 August 2021
Estimated completion	31 August 2021
Sites	1 location across France

Drugs / interventions tested

Anti-PD-1 or anti-PD-L1 — full drug profile →

Conditions studied

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies — all drugs for Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies →

Sponsor

University Hospital, Montpellier

Who can join

Eligibility, any sex, with Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04609930 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 23 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04609930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing